Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of EuHZV in Healthy Adults Aged 50 to 69 Years
NCT06409494Phase 1Active, not recruiting
- Sponsor
- EuBiologics
- Start
- Jul 2024
- Primary completion
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EuHZV in herpes zoster (HZ) (3 arms), sponsored by EuBiologics. Primary endpoints: Occurrence of immediate adverse events at 30 minutes, Occurrence of solicited adverse events at 7 days and 2 more. Started Jul 2024; status: active, not recruiting.
02
Drugs
EuHZV
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT06409494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06409494.